Related Experiment Video
Updated: Aug 22, 2025
09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
3.2K
Noninvasive Pregestational Genetic Testing of Embryos Using Smart Sensors Array
Yasmin Shibli Abu Raya1, Naama Srebnik2, Esther Rubinstein2
1Department of Chemical Engineering and Russel Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, 3200003 Haifa, Israel.
ACS Sensors
|November 14, 2022
Summary
This study introduces a novel noninvasive method for embryo genetic testing using an AI-powered nanosensor array to analyze volatile organic compounds. This approach accurately identifies genetic disorders in embryos, offering a potential alternative to invasive biopsy in in vitro fertilization (IVF).
Area of Science:
- Biotechnology
- Genetics
- Artificial Intelligence
Background:
- Current preimplantation genetic testing relies on invasive embryo biopsy, posing risks to embryo viability.
- Noninvasive methods for assessing embryo genetic health during in vitro fertilization (IVF) are lacking.
- Volatile organic compounds (VOCs) emitted by embryos may serve as biomarkers for genetic disorders.
Discussion:
- An artificially intelligent nanosensor array was employed to analyze VOCs in the culture fluid of IVF-derived embryos.
- The study demonstrated significant discrimination between embryos with genetic disorders (PKD, FRAX, HOCM, BRCA, HSCR) and their wild-type counterparts.
- High discrimination accuracies were achieved, ranging from 81% to 100% depending on the specific genetic condition.
Key Insights:
- AI-powered nanosensor analysis of embryo-emitted VOCs can noninvasively detect genetic disorders.
- This method shows promise for identifying conditions like Polycystic Kidney Disease (PKD), Fragile X Syndrome (FRAX), Hypertrophic Cardiomyopathy (HOCM), BRCA-related conditions, and Hirschsprung disease (HSCR).
- The findings support the potential for a noninvasive diagnostic approach in assisted reproductive technologies.
Outlook:
- This proof-of-concept study paves the way for developing noninvasive embryo screening tools in IVF.
- Further research could refine the nanosensor technology and expand the range of detectable genetic disorders.
- Clinical implementation could reduce the risks associated with current invasive embryo biopsy procedures.
